These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23633687)

  • 1. FDA advisory panel assesses hydrocodone prescription writing: every dentist's responsibility.
    Curro FA
    J Am Dent Assoc; 2013 May; 144(5):462-4. PubMed ID: 23633687
    [No Abstract]   [Full Text] [Related]  

  • 2. Hydrocodone prescriptions.
    Liewehr FR
    J Am Dent Assoc; 2013 Aug; 144(8):876. PubMed ID: 23904570
    [No Abstract]   [Full Text] [Related]  

  • 3. Author's response.
    Curro FA
    J Am Dent Assoc; 2013 Aug; 144(8):876-7. PubMed ID: 23904571
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA to propose hydrocodone reclassification.
    J Calif Dent Assoc; 2014 Jan; 42(1):10. PubMed ID: 25080676
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA committee: More restrictions needed on hydrocodone combination products.
    Kuehn BM
    JAMA; 2013 Mar; 309(9):862. PubMed ID: 23462764
    [No Abstract]   [Full Text] [Related]  

  • 6. REMS; red tape, or a remedy for opioid abuse?
    Porada S
    J Fam Pract; 2011 Sep; 60(9 Suppl):S55-62. PubMed ID: 22442761
    [No Abstract]   [Full Text] [Related]  

  • 7. Feeling the pain.
    Nuzback K
    Tex Med; 2015 Jan; 111(1):37-41. PubMed ID: 25624026
    [No Abstract]   [Full Text] [Related]  

  • 8. Upscheduling of hydrocodone: convenience and access vs patient safety measures.
    Schatman ME; Darnall BD
    Pain Med; 2013 Nov; 14(11):1627. PubMed ID: 24238351
    [No Abstract]   [Full Text] [Related]  

  • 9. Combating an Epidemic of Prescription Opioid Abuse.
    Pon D; Awuah K; Curi D; Okyere E; Stern CS
    J Calif Dent Assoc; 2015 Nov; 43(11):673-8. PubMed ID: 26798885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DEA reschedules hydrocodone combination products as schedule II.
    J Mich Dent Assoc; 2014 Oct; 96(10):11. PubMed ID: 25647867
    [No Abstract]   [Full Text] [Related]  

  • 11. The US Opioid Crisis: Current Federal and State Legal Issues.
    Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK
    Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An empty toolbox: hydrocodone to schedule II.
    Berger BJ
    Ann Emerg Med; 2014 Dec; 64(6):19A-21A. PubMed ID: 25606604
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent developments toward the safer use of opioids, with a focus on hydrocodone.
    Covvey JR
    Res Social Adm Pharm; 2015; 11(6):901-8. PubMed ID: 25769501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA panel recommends tighter rules for prescribing opioids.
    McCarthy M
    BMJ; 2013 Feb; 346():f1012. PubMed ID: 23412738
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA advisers support rescheduling of hydrocodone products.
    Traynor K
    Am J Health Syst Pharm; 2013 Mar; 70(5):383-4. PubMed ID: 23413158
    [No Abstract]   [Full Text] [Related]  

  • 16. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS).
    Nelson LS; Perrone J
    JAMA; 2012 Aug; 308(5):457-8. PubMed ID: 22851109
    [No Abstract]   [Full Text] [Related]  

  • 17. The FDA's Approach to the Prescription Opioid Problem.
    Woodcock J; Throckmorton DC
    Clin Pharmacol Ther; 2018 Jun; 103(6):954-955. PubMed ID: 29570773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DEA reschedules hydrocodone combination products.
    Pergolizzi JV
    Pain Pract; 2015 Feb; 15(2):95-7. PubMed ID: 25639283
    [No Abstract]   [Full Text] [Related]  

  • 19. Zohydro approval by food and drug administration: controversial or frightening?
    Manchikanti L; Atluri S; Candido KD; Boswell MV; Simopoulos TT; Grider JS; Falco FJ; Hirsch JA
    Pain Physician; 2014; 17(4):E437-50. PubMed ID: 25054396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
    Hale ME; Ma Y; Malamut R
    J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.